TENX vs TLSA

Tenax Therapeutics, Inc. vs Tiziana Life Sciences Ltd — Valuation Comparison 2026

TENX

Biotechnology
Tenax Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
33
LOW
Price
$11.69
Last close
Models
7/13
Active
VS

TLSA

Biotechnology
Tiziana Life Sciences Ltd
Quality
1.7
out of 10
Value Trap
Price
$1.46
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TENX Fair ValueTENX Upside TLSA Fair ValueTLSA Upside
Bayesian DCF Intrinsic $5.58 -52.3% $0.39 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.63 -60.4% $0.04 -97.4%
PWERM Option-Based $11.42 -2.3% $1.41 -3.8%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TENX vs TLSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TENX vs TLSA — Which Stock Is More Undervalued?

TENX scores higher with a 4.5/10 quality rating vs TLSA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tenax Therapeutics, Inc. (TENX) and Tiziana Life Sciences Ltd (TLSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TENX currently trades at $11.69 with a QOC of 4.5/10, while TLSA trades at $1.46 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).